SAB Biotherapeutics, Inc. (NASDAQ: SABS) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $8.00 price target on the stock.
Great CEOs don't just know how to make their companies more valuable—they know when it's time to move on [Fortune]
SAB Biotherapeutics Announces Departure of Chief Financial Officer [Yahoo! Finance]
SAB Biotherapeutics Announces Departure of Chief Financial Officer
SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $25.00 price target on the stock.